Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQWH2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $99,505
Award facts
- Contract value 100% obligated
- $99,504.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $99,504.78 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for STELARA 90 mg/mL syringes. The contract, issued on December 22, 2025, with an ultimate completion date of January 14, 2026, contains no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $499.9 billion initiative established to support Department of Defense pharmaceutical supply requirements across military healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, specializing in the distribution of branded and generic prescription medications, biologics, and medical consumables to the Department of Defense. The company's product portfolio includes specialty pharmaceuticals such as STELARA, an immunosuppressant biologic used in treating conditions including plaque psoriasis, psoriatic arthritis, and Crohn's disease. The PPV-G GEN V contract, awarded on November 13, 2025, with a completion date of December 31, 2036, features a 30-month base period and three 30-month option periods, positioning DMS Pharmaceutical Group as one of multiple regional prime vendors within the broader $30.3 billion acquisition strategy designed to ensure reliable pharmaceutical supply to military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FQWH2?
SPE2DR26FQWH2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 22, 2025.
How much is contract SPE2DR26FQWH2 worth?
The government has obligated $99,505 on SPE2DR26FQWH2.
Is contract SPE2DR26FQWH2 an order under another contract?
Yes. SPE2DR26FQWH2 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWH2 competed?
The extent of competition for SPE2DR26FQWH2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award